a Cold War stroke drug repurposed as a nootropic
1982-1996 (synthesized ~1982; foundational papers 1984/1991; approved as a Russian medicine ~1995)
Semax is a fragment of the same pituitary hormone that floods your body in a crisis — too short to set off the alarm, yet somehow just right for sharpening the mind.
The story starts not in Moscow but in the Netherlands, where through the 1950s-70s Dutch pharmacologist David de Wied noticed something strange: small fragments of adrenocorticotropic hormone (ACTH) — the pituitary signal that whips your adrenal glands into their stress response — could sharpen learning and memory in animals even after being stripped of any power to act on the adrenals at all. De Wied gave this odd class of molecule a name that stuck: the neuropeptide, a stress-hormone offcut that was hormonally dead but neurologically wide awake.
In the late 1970s a team at the Institute of Molecular Genetics of the USSR Academy of Sciences — physiologist Ivan P. Ashmarin and chemist Nikolai F. Myasoedov — set out to turn that curiosity into an actual Soviet drug. They fixed on the fragment ACTH(4-10), which carried the same memory-boosting quirk but had a fatal flaw: blood and brain enzymes shredded it within seconds. Around 1982 the fix proved almost comically simple — welding a three-amino-acid stabilizing cap, proline-glycine-proline, onto the tail left the brain effects untouched while extending the molecule's active life roughly twentyfold. The seven-amino-acid result got a name with blunt Soviet logic: Semax, from the Russian for 'seven amino acids' — a technical label, not a marketing one, that just happened to stick.
What came next was a long institutional grind rather than a eureka moment. A 1984 paper christened the stabilized peptide a 'stimulator of learning with prolonged action'; pharmacokinetic work into 1991 confirmed it slipped into the brain and shrugged off the enzymes that had destroyed its parent fragment; and animal studies of stroke and cerebral ischemia revealed neuroprotective, anti-inflammatory effects. After Phase I trials (1990-1994) and Phase II (1994-1996), Semax won Russian medical approval — commonly cited as 1995 — for acute ischemic stroke, later picked up optic nerve atrophy as a second indication, and in December 2011 landed on Russia's official List of Vital and Essential Drugs.
For two more decades Semax stayed all but invisible outside Russia and the former Soviet bloc. Then, in the mid-2010s, Western nootropics and biohacking circles — hunting for cognitive enhancers with real animal and human data behind them rather than pure supplement hype — dug up the old Russian literature and began importing intranasal Semax as an unregulated 'research chemical.' It has lived in that gray zone ever since: legal to buy and sell in the US as an unscheduled compound, but never evaluated by the FDA, and self-administered by a community effectively running its own uncontrolled real-world trial alongside the peptide's decades of official Russian use.
The history here — the Dutch neuropeptide origins, the Moscow timeline, the 'seven amino acids' naming, and the Russian approvals — all checks out. What's overstated is the tidy 'chemists cut out the panic and kept the smarts' framing: the fragment was simply already too short to trigger the adrenal stress response on its own, and the piece the Soviet team actually added (a proline-glycine-proline cap) was just there to stop it degrading — not a deliberately preserved 'smart' part.
Today Semax occupies a genuinely split existence that makes it a tidy case study in regulatory history. In Russia and some former-Soviet states it is a real, decades-old prescription drug for stroke and neurological conditions, sold as a nasal solution and on the government's essential-medicines list since 2011. In the US and most of the West it is the mirror image — an unapproved, unscheduled gray-market 'research chemical' bought online in vials with no FDA oversight of purity or dose. What makes that limbo notable rather than routine is that Semax actually has peer-reviewed mechanistic backing (BDNF and NGF upregulation, anti-inflammatory effects in stroke models) that most nootropics sold beside it simply don't have.
